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Treatment of proliferative lupus 
nephritis: a changing landscape
D Adu1
Grootscholten et al. report a randomized controlled trial 
comparing azathioprine plus intravenous methylprednisolone 
and oral prednisolone (AZA group) with intermittent intravenous 
cyclophosphamide and oral prednisolone (CY group) in patients with 
proliferative lupus nephritis. AZA-treated patients were more likely to 
develop non-sustained doubling of their serum creatinine, although not 
significantly so, and significantly more likely to have a relapse of their 
nephritis than CY-treated patients. 
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Th e overall survival of patients with sys-
temic lupus erythematosus and a pro-
liferative glomerulonephritis (World 
Health Organization classes III and IV) 
has improved considerably over the last 
few decades.1 Nevertheless, aft er 10 years 
of treatment, 5%–10% of patients have 
died and a further 5%–15% have devel-
oped end-stage renal failure.2,3 For rea-
sons that are not clear, survival to death 
and end-stage renal failure is much poorer 
in African Americans than in American 
or European whites. Improvement in 
outcome can be achieved only by careful 
randomized controlled trials such as the 
study of Grootscholten et al.4 (this issue). 
Th is and other recently reported rand-
omized controlled trials of therapy in 
lupus nephritis increase our options for 
management but at the same time chal-
lenge our long-held beliefs.
Depending on how it is defi ned, a sig-
nifi cant proportion of patients with lupus 
nephritis do not achieve complete remis-
sion despite treatment with cyclophos-
phamide. Th is proportion ranges from 
30% to 50%5,6 or even higher.7 Failure to 
achieve a remission of the renal disease is 
associated with a signifi cantly increased 
risk of end-stage renal failure, relapses, 
and death. In the study by Illei et al.,6 36% 
of patients did not achieve a complete or 
partial remission, and of these 9% died 
and 49% developed end-stage renal fail-
ure. Between 20% and 40% of patients 
who achieve a complete remission of 
their renal disease relapse over a mean 
follow-up of about 10 years.3,6 These 
relapses are associated with an increased 
risk of developing end-stage renal failure. 
In studies at the United States National 
Institutes of Health (NIH), a longer dura-
tion of cyclophosphamide treatment 
(up to 2 years) reduced the cumulative 
probability of relapse as compared with 
6 months of cyclophosphamide (P = 
0.006)8 but was associated with increased 
gonadal toxicity.
Any doctor who looks after patients 
with lupus nephritis knows that the 
management of these patients remains a 
challenge. It is also a source of real disa-
greement. Th e clinical presentation, his-
tology, clinical course, and responsiveness 
to treatment of lupus nephritis are heter-
ogeneous. Disagreements on the optimal 
management of lupus nephritis result in 
part from this heterogeneity and also from 
the paucity of adequately powered rand-
omized controlled trials. Several ques-
tions remain unanswered, such as (1) the 
optimal therapy for inducing remission 
and the duration of treatment required, 
(2) the optimal therapy for maintaining 
remission, and (3) the best ways of treat-
ing relapses.
The careful randomized controlled 
studies from the NIH made intermittent 
intravenous cyclophosphamide and oral 
prednisolone the accepted method for 
the management of severe lupus nephritis 
(World Health Organization classes III and 
IV).9 Pulse intravenous cyclophosphamide 
has been preferred in most centers to con-
tinuous oral cyclophosphamide, because 
it appeared to be associated with less tox-
icity. Some argue that continuous oral 
cyclophosphamide is as eff ective as pulse 
cyclophosphamide, but there have been few 
randomized controlled studies to address 
this issue. Th e major toxicities of cyclo-
phosphamide are dose dependent, and 
the intermittent regime typically leads to 
a lower dose. A recent study10 showed that 
a shorter 12-week course of intravenous 
cyclophosphamide given every 2 weeks at 
a dose of 500 mg followed by azathioprine 
was as effective as an abbreviated NIH 
regime (six monthly pulses of 0.5 g/m2 with 
the dose increased on the basis of the white 
blood cell count) followed by two quarterly 
pulses in inducing remission and prevent-
ing end-stage renal failure aft er a median 
follow-up of 72 months.
In a recent meta–analysis of randomized 
controlled studies,11 when compared with 
prednisolone on its own, cyclophospha-
mide and prednisolone reduced the risk 
of doubling of the serum creatinine (rela-
tive risk (RR) 0.59; 95% confi dence inter-
val (CI) 0.4–0.88), whereas azathioprine 
did not (RR 0.98; 95% CI 0.36–2.68). 
Neither drug reduced the risk of develop-
ing end-stage renal failure, although our 
unpublished meta-analysis shows that 
cyclophosphamide does so. Azathioprine 
reduced the risk of death (RR 0.60; 95% 
CI 0.36–0.99), whereas cyclophospha-
mide did not (RR 0.98; 95% CI 0.53–1.82). 
Lupus aff ects predominantly women of 
childbearing age, and the gonadotoxicity 
of cyclophosphamide (RR 2.18; 95% CI 
1.10–4.34) makes it an inherently unat-
tractive agent for therapy and one that is 
justifi ed by its eff ectiveness in reducing the 
risk of renal impairment and relapses.
Azathioprine is a safe drug, and many 
argued that it was safer than and prob-
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ably as eff ective as cyclophosphamide 
in the management of lupus nephri-
tis. Grootscholten et al.4 report a ran-
domized controlled trial comparing 
methylprednisolone, prednisolone, 
and azathioprine with prednisolone 
and intravenous cyclophosphamide in 
patients with mostly proliferative lupus 
nephritis. After a mean follow-up of 
5.7 years, they found that azathioprine 
was less effective, although not sig-
nifi cantly so, than cyclophosphamide 
in reducing the risk of non-sustained 
doubling of serum creatinine and was 
signifi cantly less eff ective in reducing 
relapses. Th is is important in a disease 
where relapses increase the risk of pro-
gressive renal damage. An important 
observation is that cyclophosphamide 
treatment is more eff ective in maintain-
ing remission than azathioprine. Th at is 
an issue that needs to be addressed when 
the studies of mycophenolate mofetil 
are considered.
Mycophenolate mofetil (MMF) is a 
powerful immunosuppressant that is 
licensed for renal transplantation. Pilot 
studies suggested that it might be eff ective 
together with steroids in induction treat-
ment of lupus nephritis, and this has now 
been tested by two randomized controlled 
trials. Chan et al.12 compared MMF and 
prednisolone with prednisolone and oral 
cyclophosphamide followed by azathio-
prine in 64 patients with lupus nephritis. 
In this study the dose and duration of 
treatment with MMF were increased in 
patients who were recruited later. Mean 
follow-up was 57.8 ± 18.7 months. Th ere 
was no signifi cant diff erence in the rates 
of doubling of serum creatinine, end-
stage renal failure, and relapses. Th e risk 
of amenorrhea was, however, signifi-
cantly lower with MMF than with cyclo-
phosphamide/azathioprine. Ginzler et 
al.7 randomized 140 patients with lupus 
nephritis to treatment with MMF (3 g/d) 
and prednisolone or with monthly intra-
venous cyclophosphamide (0.5–1.0 g/m2) 
and prednisolone in a 24-week study. 
Complete remission (defi ned as a return 
to within 10% of normal values of serum 
creatinine, proteinuria, and urinary sedi-
ment) was achieved in 16 of 71 patients 
treated with MMF (22.5%) and in 4 of 69 
patients treated with cyclophosphamide 
(5.8%) (P = 0.005). On follow-up, there 
was no difference in the rates of renal 
relapse, end-stage renal failure, or death. 
Both of these studies excluded patients 
with severe renal failure. One can con-
clude from these studies that MMF is 
probably as eff ective as and less toxic than 
cyclophosphamide in patients with new-
onset mild to moderate lupus nephritis. 
Further large, adequately powered rand-
omized controlled trials and longer-term 
follow-up are necessary to establish the 
role of MMF in induction treatment of 
lupus nephritis.
Contreras et al.13 compared three 
monthly intravenous cyclophosphamide 
pulses (0.5–1.0 g/m2) with azathioprine 
(1–3 mg/kg) or MMF (0.5–3.0 g/d) in 
59 patients in whom remission had been 
induced with intravenous cyclophospha-
mide. All were also treated with pred-
nisolone. Survival was higher in patients 
treated with azathioprine than in those on 
intravenous cyclophosphamide (P = 0.02). 
Although there were no signifi cant diff er-
ences in progression to renal failure, the 
composite end point of death or chronic 
renal failure was less common in MMF-
treated and azathioprine-treated patients 
than in patients treated with cyclophos-
phamide (P = 0.05 and P = 0.009, respec-
tively). Relapse-free survival was also 
higher in patients treated with MMF 
as compared with cyclophosphamide 
(P = 0.02). A criticism of this study is that 
the number of patients studied was rela-
tively small. Th us MMF may have a role as 
remission-maintenance therapy in lupus 
nephritis, but larger randomized control-
led studies are needed to confi rm this.
Recent randomized controlled trials in 
lupus nephritis are beginning to allow us 
to defi ne the role of old drugs (azathio-
prine and cyclophosphamide) and new 
drugs (MMF) in the management of lupus 
nephritis (Figure 1). Important end points 
in trials should include the risk of develop-
ing renal failure or of dying. Th is requires 
long-term follow-up and standardiza-
tion of post-remission therapy. Other 
end points include the rates of remission 
induction and relapses, as these may be 
surrogates for the development of renal 
failure. Progress will only come from such 
studies. Th e place of newer therapies for 
lupus nephritis such as anti-CD20 anti-
bodies remains to be established.
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IV). Evidence-based treatment of proliferative lupus nephritis.
618   Kidney International (2006) 70
commentar y
741–745.
9. Austin HA 3rd, Klippel JH, Balow JE et al. Therapy of 
lupus nephritis. Controlled trial of prednisone and 
cytotoxic drugs. N Engl J Med 1986; 314: 614–619.
10. Houssiau FA, Vasconcelos C, D’Cruz D et al. 
Immunosuppressive therapy in lupus nephritis: 
the Euro-Lupus Nephritis Trial, a randomized 
trial of low-dose versus high-dose intravenous 
cyclophosphamide. Arthritis Rheum 2002; 46: 
2121–2131.
11. Flanc RS, Roberts MA, Strippoli GF et al. Treatment 
of diffuse proliferative lupus nephritis: a meta-
analysis of randomized controlled trials. Am J 
Kidney Dis 2004; 43: 197–208.
12. Chan TM, Tse KC, Tang CS et al. Long-term 
study of mycophenolate mofetil as continuous 
induction and maintenance treatment for diffuse 
proliferative lupus nephritis. J Am Soc Nephrol 
2005; 16: 1076–1084.
13. Contreras G, Pardo V, Leclercq B et al. Sequential 
therapies for proliferative lupus nephritis. N Engl J 
Med 2004; 350: 971–980.
see original article on page 641
Increased cyclooxygenase-
2, hyperfiltration, 
glomerulosclerosis, and diabetic 
nephropathy: put the blame on 
the (pro)renin receptor?
G Nguyen1
Interaction between the renin–angiotensin system and 
cyclooxygenases in the kidney regulates renal microcirculation.  
Activation of the (pro)renin receptor has profibrotic effects, and now 
Kaneshiro et al. show that it also increases COX-2 synthesis. These 
results  may have therapeutic implications, as blocking (pro)renin–
receptor interaction would prevent the increase of angiotensin 
generation and prostaglandin synthesis, two phenomena underlying 
the pathogenesis of diabetic nephropathy.
Kidney International (2006) 70, 618–620. doi:10.1038/sj.ki.5001723
Diabetes mellitus is a fascinating patho-
logical situation associated with high 
prorenin and low renin concentrations 
in plasma, resulting in low plasma renin 
activity and a tissue activation of the 
renin–angiotensin system especially in 
the kidney. Renin exists in two forms, 
mature active renin and the inactive 
proenzyme prorenin (hereafter the 
term (pro)renin will refer to prorenin 
and renin collectively). Although many 
tissues can synthesize and secrete 
prorenin, the cleavage of 43 amino acids 
of the prosegment of prorenin, yielding 
mature renin, takes place only in the 
juxtaglomerular apparatus, precisely in 
the myo-epithelioid cells of the aff erent 
glomerular artery, and there is no known 
physiological processing of prorenin into 
renin in plasma or tissue (reviewed by 
Danser1). How can we reconcile the 
fact that the occurrence of microvas-
cular complications in diabetes, such 
as microalbuminuria, is correlated with 
inactive prorenin and not active renin 
levels, and the paradoxical activation of 
the renal renin–angiotensin system and 
increased angiotensin II (Ang II) genera-
tion? Because renin controls the rate-lim-
iting step of angiotensinogen cleavage in 
angiotensin I, one would expect a lower 
degree of activation of the renin–angi-
otensin system and not the contrary.
Th e (pro)renin receptor may provide 
one explanation. Th e receptor binds spe-
cifi cally renin and prorenin and, upon 
binding renin, increases its catalytic 
activity, and prorenin displays full enzy-
matic activity similar to that of mature 
renin;2 thus the receptor can be regarded 
as a means to amplify angiotensin gen-
eration at the cell surface. In addition, 
binding of renin and prorenin triggers 
extracellular signal-regulated kinase-
1/2 activation that may have profi brotic 
consequences.3 Ichihara et al. hypoth-
esized that inhibition of prorenin bind-
ing to the receptor would have benefi cial 
eff ects in diabetes. As no antagonist to 
the (pro)renin receptor is available, they 
tested a peptide against the prorenin 
‘handle region,’ a region described by 
Suzuki et al. to be involved in prorenin 
conformational change and non-proteo-
lytic activation.4 Indeed, these authors 
showed that infusion of the ‘handle 
region’ decoy peptide (HRP) was able 
to reduce local Ang II generation and 
fi brosis in an impressive set of experi-
mental rat models including streptozo-
tocin-induced diabetes,5 cardiac fi brosis 
in stroke-prone spontaneously hyper-
tensive (SHR) rats,6 and ocular infl am-
mation in endotoxin-induced uveitis.7 
Furthermore, these authors also reported 
the prevention of glomerulosclerosis by 
HRP infusion in streptozotocin dia-
betic Ang II receptor type 1a–/– mice, 
indicating that the profibrotic effect 
of prorenin–receptor interaction was 
essentially mediated by phosphorylation 
of the mitogen-activated protein kinases 
due to (pro)renin receptor activation 
and not to Ang II generation.8 These 
results raise two questions: (1) Renin 
also binds to the receptor with affin-
ity even higher than that of prorenin,2 
indicating that (pro)renin binding is not 
dependent on the prosegment that was 
cleaved during the maturation process, 
and HRP inhibits only prorenin bind-
ing. Th erefore, why should inhibition of 
prorenin binding be suffi  cient to prevent 
all receptor activation and pathogenic 
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